Results 181 to 190 of about 1,403,082 (309)

Cancer in a drop: Liquid biopsy highlights from the American Society of Clinical Oncology (ASCO) 2025 annual congress. [PDF]

J Liq Biopsy
Martinelli C, Borea R, Shivahamy M, Dipasquale A, Saldanha EF, Ghazali N, Nicolo E, Stejskal P, Pontolillo L, Reduzzi C.   +9 more
europepmc   +1 more source

Highlights from the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, USA, 12-15 May 2001 [PDF]

, 2001
Caroline Lohrisch
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. [PDF]

Transl Breast Cancer Res
Venkataraman J, Mokbel K.
europepmc   +1 more source

Clinical Oncology Society of Australia annual scientific meeting, November 1-3, 2023. [PDF]

Lancet Reg Health West Pac, 2023
Caga-Meller J.
europepmc   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines. [PDF]

Invest New Drugs
Hakariya H, Ozaki A, Tanimoto T.
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Large language model use in clinical oncology. [PDF]

NPJ Precis Oncol
Carl N, Schramm F, Haggenmüller S, Kather JN, Hetz MJ, Wies C, Michel MS, Wessels F, Brinker TJ.   +8 more
europepmc   +1 more source

Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results. Japan Clinical Oncology Group Protocol 8902

, 2000
Kaoru Kubota, Tomohide Tamura, M. Fukuoka, Kiyoyuki Furuse, H Ikegami, Y Ariyoshi, Yuichi Kurita, Nagahiro Saijo   +7 more
openalex   +1 more source